Action(s) taken or orders passed

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 6th August, 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject, we would like to inform you that the Company has received a Final Order from the ACIT Cir 7(1)(1) with the Demand Liability of Rs 23.21 Crores. The relevant details to be disclosed are as under: Sr Particulars Details 1 Name of the authority OGE to CIT-Appeal received for the GSK AY: 1984-85 on 27th Jan, 2026 and the refund received in Bank on 6th Aug, 2026 for Rs 52.00 2 Nature and details of the action(s) taken, initiated or The said Refund is received post the OGE to order(s) passed CIT-Appeal for the GSK assessment for the AY: 8 4-85. 3 Date of receipt of direction or order, including any OGE to CIT-Appeal received dated on 27th Jan, ad-interim or interim orders, or any other 2026 and the actual refund received today i.e. communication from the authority 6th Aug, 2026. 4 Details of violation(s) / contravention(s) committed or N.A. alleged to be committed 5 Impact on financial, operation, or other activities of Interest Income of Rs 42.09 Cr on GSK Refund the listed entity, quantifiable in monetary terms to the for AY: 84-85 will be credited to P/L account as extent possible Income. Kindly take the same on the record. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151